EVTCY - EVTCY STOCK NEWS

Evotec has partnered with Medical Center Hamburg-Eppendorf (UKE) to develop a first-in-class cell therapy for heart failure. This innovative approach utilizes induced pluripotent stem cells (iPSCs) to create clinically relevant heart tissue. The partnership aims to enhance patient outcomes by improving heart function, leveraging Evotec's GMP-compatible processes and UKE's Giga Patch Method. Heart failure affects over 26 million globally, with significant mortality rates. No financial details were disclosed, but the collaboration signifies a major step towards new therapeutic interventions for this critical health burden.

Evotec and STORM Therapeutics announce the selection of STC-15, a first-in-class oral small molecule inhibitor targeting METTL3, for development in cancer treatment, specifically acute myeloid leukemia. The compound was identified with Evotec’s support through its integrated IND-enabling platform, INDiGO. STORM aims to initiate clinical trials by 2021, focusing on patients with chemotherapy-refractory leukemia. This collaboration emphasizes Evotec's role in progressing innovative drug discovery in RNA epigenetics.

Evotec SE has announced the expansion of its Milton Park campus in Abingdon, UK, into a major integrated R&D center named the Dorothy Crowfoot Hodgkin Campus. This development will house up to 100 biologists and enhance high-performance small molecule discovery. The new facility will focus on in vitro pharmacology and expand its capabilities in protein sciences and structural biology. With over 600 employees, this site will enhance Evotec's global R&D capacity and strengthen partnerships within the UK biotech scene.

Evotec SE reported a 12% increase in group revenues to €360.4 million for the first nine months of 2020, with a strong like-for-like growth of 19%. The company's segments, EVT Execute and EVT Innovate, showed robust revenue growth of 14% and 21%, respectively. Adjusted EBITDA was €76.9 million, down from €93.2 million in 2019. The guidance for full-year 2020 remains unchanged, projecting revenues between €440 million and €480 million. Despite the pandemic, no significant impacts on financials were noted, with ongoing expansions and strategic partnerships enhancing future growth opportunities.

Just - Evotec Biologics has received a grant from the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator. This funding aims to optimize monoclonal antibody (mAb) candidates for treating COVID-19 in vulnerable populations in low and middle-income countries. The company will utilize its Abacus(TM) software for in silico analysis and perform cell line development for two lead mAb candidates. No financial details of the grant were disclosed, but the initiative highlights Evotec's commitment to combating COVID-19.

Evotec SE (OTC PINK:EVTCY) announced a capital increase via a private placement, issuing 11,478,315 new shares without pre-emptive rights. Mubadala Investment Company will invest €200 million for 9,182,652 shares at €21.78 each, representing approximately 5.6% of outstanding shares. Novo Holdings A/S will contribute €50 million for 2,295,663 shares, maintaining an 11% stake. The share placement was at a 2.5% discount to the five-day volume weighted average price. The capital increase aims to strengthen Evotec's position in the biotech industry while maintaining its 2020 business outlook.

Mubadala Investment Company becomes a strategic shareholder in Evotec by acquiring shares worth €200 million, representing 5.6% of outstanding shares. Novo Holdings A/S, a current shareholder, invests an additional €50 million. The total capital increase will boost Evotec’s cash reserves by €250 million. Funds will be allocated for expanding biologics, enhancing precision medicine processes, and developing drug discovery platforms. This investment is anticipated to accelerate Evotec's growth and strengthen its financial position, including a net cash position exceeding €150 million.

Evotec has received a US$ 6 million payment from Bristol Myers Squibb following the expansion of their drug discovery collaboration. This partnership aims to develop treatments for neurodegenerative diseases such as Alzheimer's. Since initiating in 2016, the collaboration has made progress in identifying disease-modifying treatments, addressing a significant unmet medical need. Evotec's innovative approach leverages its advanced iPSC technology platform, enhancing its portfolio of potential therapies.

Evotec has announced a partnership with BIOASTER to enhance research capabilities in fighting infectious diseases. This collaboration aims to develop new therapies and technologies targeting antimicrobial resistance and vaccine safety. With over 120 researchers and shared advanced infrastructures, including BSL3 laboratories, the partnership is expected to accelerate product development. The two organizations are already engaged in European projects like ERA4TB and GNA NOW, focused on addressing antibiotic resistance. This move strengthens the health ecosystem in Lyon, France.